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Background: Gastroesophageal reflux disease (GERD) is one of the most common causes of chronic cough and a
potential risk factor for exacerbation of chronic obstructive pulmonary disease (COPD). The aim of this study was to
investigate the prevalence and risk factors of GERD in patients with COPD and association between GERD and
COPD exacerbation.
Methods: Data were collected from the National Health Insurance Database of Korea. The subjects were 40 years
old and older, who had COPD as primary or secondary diagnosis codes and utilized health care resource to receive
prescriptions of COPD medication at least twice in 2009. Univariate logistic regression was performed to understand
the relationship between COPD and GERD, and multiple logistic regression analysis was performed with adjustment
for several confounding factors.
Results: The prevalence of GERD in COPD patients was 28% (39,987/141,057). Old age, female gender, medical aid
insurance type, hospitalization, and emergency room (ER) visit were associated with GERD. Most of COPD
medications except inhaled muscarinic antagonists were associated with GERD. The logistic regression analysis
showed that the presence of GERD was associated with increased risk of hospitalization (OR 1.54, CI 1.50 to 1.58,
p<0.001) and frequent ER visits (OR 1.55, CI 1.48 to 1.62, p<0.001).
Conclusions: The prevalence of GERD in patients with COPD was high. Old age, female gender, medical aid
insurance type, and many COPD medications except inhaled muscarinic antagonists were associated with GERD.
The presence of GERD was associated with COPD exacerbation.
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Exacerbations of chronic obstructive pulmonary disease
(COPD) have a significant impact on patient quality of
life and can accelerate lung function decline [1], which is
associated with increased morbidity and mortality [2,3].
Gastroesophageal reflux disease (GERD) is one of the
most common causes of chronic cough [4] and a poten-
tial risk factor for exacerbation of COPD [5-7]. GERD is
a relatively common condition, affecting 10–29% of the
western population [8] and 3–12% of Korean adults [9].* Correspondence: jinhwalee@ewha.ac.kr
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reproduction in any medium, provided the orGER can heighten bronchial reactivity and microaspiration
[10-13]. Abnormal GER was objectively assessed and clearly
associated to lung diseases [14,15]. Laryngopharyngeal
sensitivity is important in preventing pulmonary aspir-
ation. Patients with cough and GERD have significantly
reduced laryngopharyngeal sensitivity to air stimuli
compared with healthy subjects [16]. COPD patients
have flat diaphragm and increased intra-abdominal
and negative intra-thoracic pressure, which could
aggravate GER [17]. In addition, medications such as
theophylline and inhaled beta-2 agonists may decrease
the lower esophageal sphincter pressure, could facilitate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that GERD is more common in patients with COPD
than that in those without COPD [20-22]. Also it has
been suggested that an increase in the frequency of
COPD exacerbation can be associated with the presence
of GERD [6,7,23,24].
We used the National Health Insurance Database of
Korea and tried to answer three questions. First question
was the prevalence of GERD in patients with COPD.
Second one was which factors are associated with GERD
in COPD patients. Third was whether the presence of
GERD is associated with exacerbation of COPD even
after adjusting confounding factors.
Methods
Data source and ethical considerations
The present study used the National Health Insurance
claims data for medical services provided to Koreans
aged ≥ 40 years between January 1, 2009 and December
31, 2009. These data were provided by the Korean
Health Insurance Review and Assessment Service
(HIRA), which was established to review claims data and
assess healthcare in Korea and is under the responsibility
of a single agency independent from insurers, providers,
and other interested parties. All Koreans are covered
under the national health insurance system, and the
HIRA database contains all information regarding
submitted claims and prescriptions.
The HIRA claims database comprises general item,
medical treatment, diagnosis, and prescription databases.
The general item database contains information such as
patient identifier, age, sex, and insurance type; hospital
name, type, location, and medical department; and med-
ical cost, number of days hospitalized and/or receiving
outpatient, intensive care unit (ICU), and/or emergency
room (ER) care. The medical treatment database con-
tains information such as patient identifier, detailed
medical treatment records, and drug administration
(brand name, total days of medication, single dose, daily
dose, and unit cost). The diagnosis database contains
information such as patient identifier, main diagnosis,
and submain diagnoses, recorded according to the
International Classification of Diseases, 10th Revision
(ICD-10). The prescription database contains informa-
tion such as patient identifier and outpatient prescrip-
tions. All databases were linked using a mutual
identifier.
The National Evidence-Based Healthcare Collaborat-
ing Agency (NECA) ethics committee approved the
present study (PIRB11-022).
Study population
The subjects of the current study were patients
aged ≥40 years with COPD recorded as ICD-10 codesJ42.x–J44.x (except J430) for the principal or additional
diagnoses who were given prescriptions including at
least one of the following medications (including oral,
injected, or inhaled), at least twice per year: combina-
tions in a single inhaler of inhaled corticosteroids
(ICSs) and long-acting beta-2 agonists (LABAs), long-
acting muscarinic antagonists (LAMAs), LABAs,
short-acting muscarinic antagonists (SAMAs), inhalers
with both short-acting beta-2 agonists (SABAs) and
SAMAs, oral beta-2 agonists, or theophylline.
Patients with more than one claim per year due to
cancer (C00.x–C97.x) and/or cerebrovascular disease
(I60.x–I69.x) were excluded from this study because the
enormous expenses claimed for treatment of these dis-
eases were difficult to distinguish from COPD- and
GERD-related medical services. Additionally, through
consultation with six physicians of pulmonary medicine,
we decided to exclude patients with more than one
claim per year for hiatal hernia (K449), gastric surgery
(K910–K913), Zollinger-Ellison syndrome (E164), sys-
temic sclerosis (M34), achalasia (K220), pyloric obstruc-
tion (K311–K315), obesity (E66.x), alcoholic liver disease
(K70.x), or ascites (K7151, R18, C786, A1830) because
these diseases increase the risk for GERD.
Among subjects in the present study, 39,987 patients
with COPD used medical services more than once per
year for GERD (K21, K210, K219), and 101,070 patients
with COPD did not have GERD.
Measures
Baseline characteristics
The variables considered to be baseline characteristics
were sex, age, insurance type, hospitalization and ICU
hospitalization, number of ER visits, presence of chest X-
rays, spirometry, chest CT, esophagogastroduodenoscopy,
24-h esophageal pH monitoring and esophagography,
COPD severity, and comorbidity. The ‘severe’ COPD group
comprised patients who visited a tertiary medical institu-
tion and were prescribed ICS + LABA + LAMA, ICS +
LABA + oral corticosteroid (OCS), or LAMA + OCS
more than once per year, and the ‘not severe’ group com-
prised the remaining study subjects. ER visits were defined
as cases in which an outpatient or hospitalization claim
was made for emergency medical service fees or in which
additional holiday/night service fees were incurred. Co-
morbidities included ischemic heart disease (I20.x–I25.x,
except I20.1), osteoporosis (M80.x–M82.x), depressive dis-
order (F32.x–F33.x), arthritis (M05.x–M09.x, M13.x), dia-
betes mellitus (E10.x–E14.x), congestive heart failure (I50,
I50.0, I50.1, I50.9), hypertension (I10.x), anemia (D50.x–
D53.x, D63.x), metabolic syndrome (E66, E78.0, E78.4,
E78.5), Barrett’s esophagus (B227), gastric ulcer (K25.x),
duodenal ulcer (K26.x), peptic ulcer (K27.x–K28.x), and
gastroduodenitis (K29.x).
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Medications considered in the present study included
ICSs, ICSs/LABAs, LAMAs, LABAs, leukotriene re-
ceptor antagonists (LTRAs), OCSs, SAMAs, SABAs,
SABAs/SAMAs, oral beta-2 agonists, and theophylline
covering all form of drug such as oral medications,
injections, and inhalations.
Exacerbation of COPD
Exacerbation was defined as hospitalization or ER visits.
Only subjects who were admitted to the department of
internal medicine and received systemic corticosteroids
during at least three days or recorded as ICD code for
COPD exacerbation were included. Cases receiving
systemic corticosteroids and inhaled short-acting bron-
chodilators at ER visits were included.
Statistical analyses
Data were analyzed using the SAS statistical program
(ver. 9.2 [SAS Institute]); details of the analytical
methods were as follows.
First, frequencies and percentages were calculated to
enable comparison of baseline characteristics between
COPD patients with GERD and those without GERD;
the chi-squared test was used for categorical data, and
the t-test was used for continuous data.
Second, the difference in medication usage between
groups was determined using frequencies and
percentages.
Third, univariate logistic regression was performed to
understand the relationship between the general charac-
teristics of patients with COPD and the presence of
GERD, and multiple logistic regression was performed,
with general characteristic variables included in the
model.
Fourth, univariate logistic regression was performed to
understand the relationship between the co-morbidity of
patients with COPD and the presence of GERD, and the
relationship between the medication usage of patients
with COPD and the presence of GERD. Additionally,
multiple logistic regression analysis was performed with
adjustment for sex, age, type of health insurance, history
of hospitalization and ICU hospitalization, category of
ER visit, and COPD severity.
Fifth, univariate logistic regression was performed to
understand the relationship between the presence of
GERD in patients with COPD and the exacerbation of
COPD, and multiple logistic regression was performed
with adjustment for sex, age, type of health insurance,
and COPD severity.
Results
The prevalence of GERD in patients with COPD was
28% (39,987/141,057).General characteristics of patients with COPD
according to the presence or absence of GERD were
summarized in Table 1. COPD patients with GERD
had more hospitalization and ER visits than those with-
out GERD (all p < 0.001), whereas there was no differ-
ence of ICU hospitalization between two groups. More
patients with COPD and GERD used medical services
for treatment of all kinds of comorbidity than did those
without GERD (all p < 0.001; Table 1).
Medication used for both group was summarized in
Table 2.
A regression model including general characteristics
indicated that more female than male patients with
COPD had GERD and more patients in their 50s, 60s,
and 70s had GERD compared with those in their 40s.
More GERD was observed in the medical aid group
compared with the health insurance group, and in sub-
jects with hospitalization experience compared with sub-
jects without hospitalization. Less GERD was observed
in subjects with ICU hospitalization than in those with-
out. More GERD were observed in subjects with ER
visits compared with those without (Table 3).
After adjusting for sex, age, type of health insurance,
hospitalization, ICU hospitalization, category of ER visit,
and COPD severity, more patients with COPD and
GERD had comorbidities except congestive heart failure.
More GERD was observed among patients using ICSs,
ICSs/LABAs, LTRAs, OCSs, oral beta-2 agonists, and
theophylline (all p < 0.001). However, less GERD was ob-
served in association with SAMAs use [odds ratio (OR)
0.96, 95% confidence interval (CI) 0.93 to 0.99; Table 4].
After adjusting for sex, age, type of health insurance,
and COPD severity, the regression model demonstrated
that COPD exacerbation was more prevalent among pa-
tients with GERD than among those without GERD, as
indicated by more hospitalization (OR 1.54, 95% CI 1.50
to 1.58) and ER visits (OR 1.55, 95% CI 1.48 to 1.62;
Table 5).
Discussion
To the best of our knowledge, this is the first nationwide
study of the largest number of COPD patients to investi-
gate the prevalence of GERD and the association be-
tween COPD and GERD. The prevalence of GERD in
patients with COPD was 28%, which is very high since
the prevalence in Korean general population is around
12%. It is similar to previous ones reported in Japan
[7,24], and lower than the others, which were 32%–37%
in the USA and 53.6% in Iran [6,20,23], even though
these studies investigated only a small number of pa-
tients with COPD. Some of them showed higher preva-
lence in COPD patients compared with controls [7,20].
These support that GERD is one of the most common
comorbidities in patients with COPD.
Table 1 General characteristic of subjects with COPD, classified according to the presence of GERD
Variables
COPD with GERD COPD without GERD
p
No. (%) No. (%)
Total 39,987 (100.0) 101,070 (100.0)
Sex <0.001
Male 22,967 (57.4) 61,674 (61.0)
Female 17,020 (42.6) 39,396 (39.0)
Age (years)
Mean ± SD 68.86 ± 10.18 69.71 ± 11.67 <0.001
40–49 1,904 (4.8) 5,243 (5.2) <0.001
50–59 5,349 (13.4) 13,052 (12.9)
60–69 11,954 (29.9) 26,801 (26.5)
70–79 15,239 (38.1) 37,329 (36.9)
80+ 5,541 (13.9) 18,645 (18.4)
Type of insurance <0.001
Health insurance 32,823 (82.1) 85,755 (84.8)
Medical aid 7,164 (17.9) 15,315 (15.2)
Hospitalization <0.001
Never 24,179 (60.5) 70,547 (69.8)
Ever 15,808 (39.5) 30,523 (30.2)
ICU hospitalization 0.377
Never 39,817 (99.6) 100,605 (99.5)
Ever 170 (0.4) 465 (0.5)
No. of ER visits
Mean ± SD 1.65 ± 1.24 1.50 ± 1.02 <0.001
0 31,260 (78.2) 84,116 (83.2) <0.001
1–2 7,446 (18.6) 15,121 (15.0)
3–4 984 (2.5) 1,506 (1.5)
5+ 297 (0.7) 327 (0.3)
Chest X-ray <0.001
Never 22,671 (56.7) 65,494 (64.8)
Ever 17,316 (43.3) 35,576 (35.2)
Spirometry <0.001
Never 23,353 (58.4) 65,891 (65.2)
Ever 16,634 (41.6) 35,179 (34.8)
Chest CT 0.055
Never 39,583 (99.0) 100,159 (99.1)
Ever 404 (1.0) 911 (0.9)
Esophagogastroduodenoscopy <0.001
Never 27,923 (69.8) 94,638 (93.6)
Ever 12,064 (30.2) 6,432 (6.4)
24-h esophageal pH monitoring <0.001
Never 39,974 (100.0) 101,067 (100.0)
Ever 13 (0.0) 3 (0.0)
Esophagography <0.001
Never 39,352 (98.4) 100,566 (99.5)
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Table 1 General characteristic of subjects with COPD, classified according to the presence of GERD (Continued)
Ever 635 (1.6) 504 (0.5)
COPD severity <0.001
No 32,629 (81.6) 84,427 (83.5)
Yes 7,358 (18.4) 16,643 (16.5)
Comorbidity
Ischemic heart disease 8,262 (20.7) 15,696 (15.5) <0.001
Osteoporosis 8,723 (21.8) 15,281 (15.1) <0.001
Depressive disorder 4,838 (12.1) 6,442 (6.4) <0.001
Arthritis 10,299 (25.8) 18,035 (17.8) <0.001
Diabetes mellitus 10,426 (26.1) 22,478 (22.2) <0.001
Congestive heart failure 3,819 (9.6) 8,661 (8.6) <0.001
Hypertension 20,734 (51.9) 48,802 (48.3) <0.001
Anemia 2,354 (5.9) 3,973 (3.9) <0.001
Metabolic syndrome 9,296 (23.2) 16,428 (16.3) <0.001
Barrett’s esophagus 23 (0.1) 4 (0.0) <0.001
Gastric ulcer 14,308 (35.8) 17,940 (17.8) <0.001
Duodenal ulcer 2,489 (6.2) 2,404 (2.4) <0.001
Peptic ulcer 8,856 (22.1) 13,657 (13.5) <0.001
Gastroduodenitis 36,196 (90.5) 77,151 (76.3) <0.001
No. = number of subjects; SD = standard deviation; ICU = intensive care unit; ER = emergency room.
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from the previous studies. One is that inhaled
anticholingergics may decrease or, at least, not increase
risk of GERD, whereas a previous study reported that
relative risk of GERD increased with using inhaled
anticholinergics [22]. In another study, the effect of
medication was not statistically significant or hard to be
evaluated because COPD patients are usually treated by
multiple medications and have both pulmonary and
other systemic problems [21]. Our hypothesis is thatTable 2 Medication utilization of patients with COPD, classifie











Oral beta-2 agonists 23,530 (32
Theophylline 33,859 (46
No. = number of subjects; ICS = inhaled corticosteroid; LABA = long-acting beta-2 a
antagonist; OCS = oral corticosteroid; SAMA = short-acting muscarinic antagonist; SAinhaled anticholinergics might reduce GER through
suppressing cough. They have been used for chronic
cough [25], which is one of the most common symptoms
in COPD patients. Chronic bronchitis and GERD are
the most common causes of chronic cough [26].
Ipratropium has been effective even for cough hypersen-
sitivity induced by upper respiratory tract infection [27].
Tiotropium inhibits cough reflex sensitivity to capsaicin
in subjects with acute viral upper respiratory tract infec-
tion [28]. The antitussive effect of tiotropium may occurd according to the presence of GERD













gonist; LAMA = long-acting muscarinic antagonist; LTRA = leukotriene receptor
BA = short-acting beta-2 agonist.
Table 3 Association of GERD with general characteristics in patients with COPD
Unadjusted Adjusted*
OR 95% CI p OR 95% CI p
Sex
Male 1 (ref) 1 (ref)
Female 1.16 (1.13, 1.19) <0.001 1.22 (1.19, 1.25) <0.001
Age (years)
40–49 1 (ref) 1 (ref)
50–59 1.13 (1.06, 1.20) <0.001 1.15 (1.08, 1.22) <0.001
60–69 1.23 (1.16, 1.30) <0.001 1.26 (1.19, 1.34) <0.001
70–79 1.12 (1.06, 1.19) <0.001 1.10 (1.04, 1.17) <0.001
80+ 0.82 (0.77, 0.87) <0.001 0.75 (0.71, 0.80) <0.001
Type of insurance
Health insurance 1 (ref) 1 (ref)
Medical aid 1.22 (1.19, 1.26) <0.001 1.15 (1.12, 1.19) <0.001
Hospitalization
Never 1 (ref) 1 (ref)
Ever 1.51 (1.48, 1.55) <0.001 1.46 (1.42, 1.50) <0.001
ICU hospitalization
Never 1 (ref) 1 (ref)
Ever 0.93 (0.78, 1.10) 0.385 0.68 (0.57, 0.82) <0.001
Number of ER visits
0 1 (ref) 1 (ref)
1–2 1.33 (1.29, 1.37) <0.001 1.11 (1.07, 1.15) <0.001
3–4 1.76 (1.62, 1.91) <0.001 1.40 (1.29, 1.53) <0.001
5+ 2.44 (2.09, 2.86) <0.001 1.87 (1.59, 2.21) <0.001
COPD severity
No 1 (ref) 1 (ref)
Yes† 1.14 (1.11, 1.18) <0.001 1.02 (0.99, 1.06) 0.186
OR = odds ratio; ICU = intensive care unit; ER = emergency room.
*Adjusted for sex, age, type of insurance, hospitalization, ICU hospitalization, number of ER visits by category, and COPD severity.
†The ‘severe’ group comprised patients who visited a tertiary medical institution and were prescribed ICS + LABA + LAMA, ICS + LABA + oral corticosteroid (OCS),
or LAMA + OCS more than once per year.
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itionally, tiotropium reduced lung inflammation in a
mouse model of chronic GER [29]. Even though ICSs
have been known to be effective for chronic cough,
especially asthma [26], our subjects exclusively had
COPD. The prevalence of GER was reported to increase
according to use of ICS in COPD patients [22], which is
consistent with our result. Combined inhalers of ICS
and LABA have been popular in Korea, whereas use of
LABA alone was very limited because representative
LABAs such as salmeterol or formoterol were no longer
imported or produced. The reason was that salmeterol
as a single agent without ICS seemed to increase respira-
tory mortality in patients with asthma [30], which made
physicians hesitate to prescribe LABA without ICS even
for COPD. Therefore it is inadequate to evaluate theireffects on GERD. When a patient takes variable drugs at
the same time, as well as COPD medication, drug inter-
action will happen.
Another different thing is that ICU admission due to
COPD exacerbation was not associated with GERD. It
may be possible for COPD patients with GERD to com-
plain more cough or heartburn and feel exacerbation
earlier than do those without GERD, which make them
more frequently have unscheduled visit or ER visit, lead-
ing to hospitalization to general ward but not to ICU.
The other possibility is that patients with COPD to be
admitted to ICU do not have chance to be examined
whether they have GERD or they are too dyspneic to
present any symptoms of GERD. Despite of higher pro-
portion of comorbidities in patients with COPD and
GERD, the rate of ICU admission was lower than those
Table 4 Association of GERD with comorbidities and medication utilization in patients with COPD
Unadjusted Adjusted*
OR 95% CI p OR 95% CI p
Comorbidity
Ischemic heart disease 1.42 (1.38, 1.46) <0.001 1.31 (1.27, 1.35) <0.001
Osteoporosis 1.57 (1.52, 1.61) <0.001 1.46 (1.42, 1.51) <0.001
Depressive disorder 2.02 (1.95, 2.10) <0.001 1.87 (1.79, 1.94) <0.001
Arthritis 1.60 (1.55, 1.64) <0.001 1.55 (1.51, 1.60) <0.001
Diabetes mellitus 1.23 (1.20, 1.27) <0.001 1.14 (1.11, 1.17) <0.001
Congestive heart failure 1.13 (1.08, 1.17) <0.001 1.04 (0.99, 1.08) 0.078
Hypertension 1.15 (1.13, 1.18) <0.001 1.11 (1.09, 1.14) <0.001
Anemia 1.53 (1.45, 1.61) <0.001 1.39 (1.32, 1.46) <0.001
Metabolic syndrome 1.56 (1.52, 1.61) <0.001 1.45 (1.41, 1.49) <0.001
Barrett’s esophagus 14.46 (5.01, 41.73) <0.001 15.10 (5.21, 43.79) <0.001
Gastric ulcer 2.58 (2.52, 2.65) <0.001 2.45 (2.38, 2.51) <0.001
Duodenal ulcer 2.72 (2.57, 2.88) <0.001 2.65 (2.51, 2.81) <0.001
Peptic ulcer 1.82 (1.77, 1.88) <0.001 1.74 (1.69, 1.79) <0.001
Gastroduodenitis 2.96 (2.85, 3.07) <0.001 2.82 (2.71, 2.92) <0.001
Drug
ICS 1.33 (1.29, 1.38) <0.001 1.13 (1.09, 1.17) <0.001
ICS/LABA 1.14 (1.11, 1.16) <0.001 1.05 (1.02, 1.08) <0.001
LAMA 1.06 (1.03, 1.09) <0.001 0.99 (0.96, 1.02) 0.567
LABA 1.12 (0.75, 1.67) 0.568 1.11 (0.74, 1.65) 0.624
LTRA 1.35 (1.31, 1.39) <0.001 1.27 (1.23, 1.30) <0.001
OCS 1.45 (1.42, 1.49) <0.001 1.37 (1.34, 1.40) <0.001
SAMA 1.20 (1.17, 1.24) <0.001 0.96 (0.93, 0.99) 0.015
SABA 1.19 (1.16, 1.22) <0.001 1.02 (0.99, 1.04) 0.237
SABA/SAMA 1.02 (0.95, 1.10) 0.627 0.97 (0.90, 1.04) 0.339
Oral beta-2 agonists 1.16 (1.13, 1.19) <0.001 1.11 (1.09, 1.14) <0.001
Theophylline 1.15 (1.11, 1.19) <0.001 1.10 (1.07, 1.14) <0.001
OR = odds ratio; ICS = inhaled corticosteroid; LABA = long-acting beta-2 agonist; LAMA = long-acting muscarinic antagonist; LTRA = leukotriene receptor
antagonist; OCS = oral corticosteroid; SAMA = short-acting muscarinic antagonist; SABA = short-acting beta-2 agonist.
*Adjusted for sex, age, type of health insurance, hospitalization, ICU hospitalization, number of ER visits by category, and COPD severity.
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rate was higher. There would be the third possibility. In this
study, prescriptions of proton pump inhibitors (PPIs) were
given for COPD patients with GERD more frequently than
those without GERD (data are not shown). PPIs decreaseTable 5 Association of GERD with exacerbation in patients wi
Hospitalization
OR 95% CI p OR
GERD
No 1 (ref) 1 (ref)
Yes 1.51 (1.48, 1.55) <0.001 0.92
GERD*
No 1 (ref) 1 (ref)
Yes 1.54 (1.50, 1.58) <0.001 0.93
ICU = intensive care unit; ER = emergency room; OR = odds ratio.
*Adjusted for sex, age, type of health insurance, and COPD severity.frequency of GERD symptoms such as cough [31], which
would rather prevent COPD patients from progression to
ICU admission. One small prospective study demonstrated
that PPIs reduced the number of exacerbation in COPD pa-
tients without GERD [32].th COPD
ICU ER visit (0–1 vs. ≥2)
95% CI p OR 95% CI p
1 (ref)
(0.78, 1.10) 0.377 1.55 (1.48, 1.62) <0.001
1 (ref)
(0.78, 1.11) 0.441 1.55 (1.48, 1.62) <0.001
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adjusting several factors such as age, gender, type of
health insurance, and COPD severity, showed that the
presence of GERD was independently associated with
COPD exacerbation such as hospitalization or frequent
ER visits. Since lung function data were not available in
the present study, definition of severe COPD was based
upon medication information and health care resource
utilization. Although the degree of airflow limitation has
been used as one of the most important criteria of
COPD severity, it does not always reflect dyspnea, exer-
cise capacity, quality of life, or exacerbation frequency
[33]. Recently updated Global initiative for chronic Ob-
structive Lung Disease (GOLD) emphasizes combined
assessment of COPD, which includes symptoms and risk
of exacerbations as well as degree of airflow limitation
[3]. To supplement our weakness, patients with severe
COPD were defined as those who satisfied both of the
followings. One is that they used a tertiary health care
resource, which means respiratory specialist’s care, and
the other is that they received medications for maximum
effect such as triple therapy (ICS + LABA + LAMA) or
OCS-containing long-acting bronchodilator, which may
mean medication for exacerbations. These are possible
under nationwide health insurance system of Korea,
which divide health care resources into primary, second-
ary and tertiary and recommend people to use those step
by step. Previous studies observed very small number of
patients and simply compared frequency of exacerbation
in COPD patients with GERD with in those without
GERD [6,7,23,24]. They did not fully consider clinically
important confounding factors such as age, gender, and
COPD severity. Moreover, in two reports of them,
COPD patients with GERD showed lower lung function
as well as higher frequency of exacerbation than did
those without GERD [23,24]. Therefore it might be hard
to conclude whether frequent exacerbation was related
to the presence of GERD or severe airflow limitation.
Our study is also limited by its retrospective and cross-
sectional design, and thus we cannot definitely conclude
that GERD causes exacerbations of COPD. However, in
a recent prospective study, patients with COPD and
GERD had more exacerbation and hospitalization than
in those without GERD, with crude relative risks of 3.42
and 3.66, respectively [24]. Since they excluded patients
taking drugs for acid suppression, their relative risks
may be higher than odds ratio in this study reflecting
real world.
There are several limitations of this study. GERD was
defined only by diagnosis codes even though about one
third of GERD patients performed diagnostic tests re-
lated to GERD. In Korea, diseases of upper gastrointes-
tinal (UGI) tract are more common than those in
western countries and the incidence of stomach cancerhas been the highest among all types of cancer. There-
fore, as a health screening program of the Korean
National Health Insurance System, all people can receive
one of EGD or UGI series every two years from the age
of 40 years. Nevertheless there might be a selection bias
since symptomatic patients are likely to receive a diag-
nostic test. Definition of COPD was based on both of
diagnosis codes and prescription data, which were exclu-
sively determined by physicians. Although 37% of our
subjects performed spirometry, this figure includes both
general physicians and specialists. To exclude asthma
patients, we excluded those receiving only LTRA or only
ICS or only SABA. Nevertheless, there was still a possi-
bility that some of our subjects may have asthma. As
considering this, we additionally analyzed each data from
only male or from subjects with prescription including
LAMA, which is specific for COPD (Additional file 1:
Table S1 and Table S2). Both analyses showed the same
trend as Table 5. Since we used health insurance claim
data, relatively important clinical data such as smoking
history, lung function, and body mass index cannot be
quantified although we tried to exclude patients with
asthma or those with obesity or other diseases increasing
risk of GERD by using both diagnosis codes and pre-
scription data. Relatively not severe exacerbation such as
unscheduled clinic visits or medication change were not
included. Also, our definition of exacerbation might
exclude some patients receiving only antibiotics without
systemic corticosteroid. However, despite of these
limitations, the present study clearly exhibits various
interactive relationships between COPD and GERD.
Although it would be hard to conclude complex rela-
tionship between COPD and GERD considering own se-
verity and specific medications for both diseases and
their interactions, we need to pay more attention to un-
raveling the heterogeneous causes of exacerbations.
Conclusions
GERD is one of the most common comorbidities and a
factor associated with exacerbation in patients with
COPD. COPD-related medications except inhaled anti-
cholinergics are associated with increased risk of GERD.
Additional files
Additional file 1: Table S1. Association of GERD with exacerbation in
male patients with COPD. Table S2 Association of GERD with
exacerbation in patients with COPD receiving LAMAs.
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